

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Theis et al.

Examiner: **To Be Assigned**

Art Unit: **To Be Assigned**

Application No.: **10/594,419**

I.A. Filing Date: **April 8, 2005**

Title: **Dual-transfected Cells Lines As In Vitro
Screening Tools For Pharmaceutical
Compound Profiling: A Model For
Hepatobiliary Elimination**

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.H./

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



Ann Marie Szczepanik, Reg. No. 52,267
Attorney/Agent for Applicant

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4757
Telefax (908) 231-2626
sanofi-aventis Docket No. DEAV2004/0025 US PCT

PTC/SB/08A (10-93)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible][illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND BY AIR MAIL. MAILING ADDRESS: MAIL STOP 100, MISSOURI PATENT OFFICE, WASHINGTON, DC 20231

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.H./

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)

Approved for use through 10/31/99. CMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/594,419
		Filing Date	09-26-2006
		First Named Inventor	THEIS et al.
		Group Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
		Attorney Docket Number	DEAV2004/0025 - US - PCT
Sheet	2	of	2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CUI et al., Vectorial Transport by Double-Transfected Cells Expressing the Human Uptake Transporter SLC21A8 and the Apical Export Pump ABCC2, Molecular Pharmacology, Vol. 60, No. 5, 2001, pp. 934-943	
		HARRIS et al., Taurocholate transport by hepatic and intestinal bile acid transporters is independent of FIC1 overexpression in Madin-Darby canine kidney cells, J. of Gastroenterology & Hepatology, Vol. 19, No. 7, July 2004, pp. 819-825	
		KAGAWA et al., Bile Acid Transport Activity And Intracellular Distribution of PF1C2 Mutants in MDCKII Cells Coexpressing NTCP and BSEP, Hepatology, Vol. 38, No. 4, Suppl. 1, 2003, p. 473	
		MITA et al., Vectorial transport of bile salts across MDCK cells expressing both rat Na ⁺ -taurocholate cotransporting polypeptide and rat bile salt export pump, Am. J. of Physiology - Gastrointestinal and Liver Physiology, Vol. 288, No. 1, Jan. 2005, pp. G159-G167	
		SASAKI et al., Transcellular Transport of Organic Anions Across a Double-Transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2), J. of Biological Chemistry, Vol. 277, No. 5, Feb. 22, 2002, pp. 6497-6503	
		SUN et al., Sorting of rat liver and ileal sodium-dependent bile acid transporters in polarized epithelial cells, American Journal of Physiology, Vol. 275, No. 5, Part 1, Nov. 1998, pp. G1045-G1055	

Examiner Signature	/Kelaginamane Hiriyanna/ (11/06/2009)	Date Considered	11/06/2009
-----------------------	---------------------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND THIS DOCUMENT TO ANY OTHER AGENCIES. SEND TO: Assistant Commissioner for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.H./